Publications
Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England
1 January 2016
This paper reports the methods and findings from the EQ-5D-5L value set for England study. The value set is derived from the stated preference data of…
New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data
1 January 2016
This paper provides details of how the EQ-5D-5L value set was derived, focusing on the methods used to model the stated preference data. Results for different…
Cost-per-QALY in the US and Britain: Damned if You Do and Damned if You Don’t
1 December 2015
Professor Weinstein presents a comprehensive analysis of the differences in attitudes between the US and the UK around how cost-effectiveness analysis (CEA) fits into the health…
Model of Behaviour within Fuzzy Budget Constraints
1 December 2015
This paper presents a model to capture the behaviour of health sector decision makers when making resource allocation decisions on the level and mix of healthcare…
Dementia: The R&D Landscape
1 November 2015
This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health.
Data Governance Arrangements for Real-World Evidence
1 November 2015
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is…
Estimation of Future Cases of Dementia from Those Born in 2015
1 October 2015
The estimates of future cases of dementia are a result of work commissioned by Alzheimer’s Research UK. The estimates were based on three components:… The estimates…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if…
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
1 August 2015
Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the…